About

Orio Therapeutics originates from the research work of its two co-founders in the field of regenerative medicine and protein engineering. The company is based on a patented technology they developed at Monash University, Australia, allowing them to integrate a 'built-in' delivery system for any therapeutic protein. Based on the Swiss roots of the co-founders and the Australian origin of the technology, Orio Therapeutics is taking this opportunity to develop its activities in Monthey and Melbourne. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients (STEMI) . About Orio Therapeutics SA Orio Therapeutics is a biotechnology company dedicated to unlocking the power of protein engineering and targeted drug delivery for the creation of next-generation regenerative medicines. The company’s innovative platform addresses fundamental limitations in current treatments, promising increased effectiveness and reduced side effects across various therapeutic areas. Orio Therapeutics operates with headquarters at the BioArk Technological Site in Monthey, Valais, Switzerland, and a secondary location at Monash University in Melbourne, Australia. About Orio Therapeutics SA Orio Therapeutics is a biotechnology company dedicated to unlocking the power of protein engineering and targeted drug delivery for the creation of next-generation regenerative medicines. The company’s innovative platform addresses fundamental limitations in current treatments, promising increased effectiveness and reduced side effects across various therapeutic areas. Orio Therapeutics operates with headquarters at the BioArk Technological Site in Monthey, Valais, Switzerland, and a secondary location at Monash University in Melbourne, Australia. Orio Therapeutics is a biotechnology company focused on revolutionizing protein therapeutics through its innovative drug delivery platform. Our core technology, originating from research at Monash University, allows us to engineer virtually any therapeutic protein with a "built-in" system that binds to the extracellular matrix (ECM). This localized delivery approach minimizes drug diffusion, enabling the use of significantly lower doses, enhancing efficacy, improving safety, and reducing costs. While we are initially focused on developing OTX-001 for myocardial infarction, we are actively exploring the broad applicability of our ECM-binding technology to other therapeutic areas where targeted protein delivery can provide significant clinical benefits.